Aeon (Switzerland).

What Aeon Switzerland actually is

The Swiss equivalent of Prenuvo in business model — imaging-led screening, no in-house treatment programme, network of partner clinics rather than a single flagship site. Operating since 2023, primarily out of Zurich and Bern, with whole-body MRI as the centre of gravity and a biomarker plus optional genetic layer wrapped around it.

Three tiers. Starter (CHF 2,490) is the whole-body MRI plus brain AI analysis plus 22 baseline biomarkers. Plus (CHF 2,990) adds body composition. Premium (CHF 6,990) extends to 70+ biomarkers, genetic analysis, optional DEXA, and an explicit longevity consultation.

What you get

The MRI is the centrepiece — high-resolution whole-body imaging covering head, neck, chest, abdomen, pelvis, spine, joints and major vessels in a single examination. Reading is by Aeon’s network of credentialled Swiss radiologists, with AI augmentation as a structured aid. The brain MRI sub-protocol is positioned as a screen for early neurological signal.

The biomarker layer scales meaningfully across tiers — at Starter, 22 markers is materially shallower than the YEARS Core panel; at Premium, 70+ markers approaches but doesn’t match the upper-tier outpatient depth.

On the model

Aeon does not run an in-house treatment programme. There is no peptide infusion suite, no hormone management division, no IV NAD+ ladder. Findings from the workup are referred back to the patient’s existing physician network, which keeps the financial geometry clean. We credit this structurally — for an imaging-led practice, the absence of a treatment-revenue path is the right architecture.

What it does mean: if your reading of the MRI surfaces something that needs clinical action, Aeon doesn’t manage that pathway directly. You take the report, you see your GP or specialist, and the workup proceeds from there. For the patient who already has that network, this is fine. For the patient looking for end-to-end care under one roof, it’s not.

Where the evidence question lives

Whole-body MRI screening in asymptomatic adults remains contested at the population-recommendation level. The major radiological societies have not endorsed it as routine screening, in large part because of the false-positive cost — incidental findings that turn out to be benign, with workup, biopsy and anxiety implications.

Aeon’s communication around this is, in our reading, more careful than the marketing copy at some American competitors. Patients are oriented to the trade-off at intake. We score it accordingly.

The verdict

For the Swiss-resident reader who specifically wants a whole-body MRI screen with a credible Swiss radiology network — and is fine doing the clinical action elsewhere — Aeon is the right match. Comparable in business model to Prenuvo on the US side; meaningfully cheaper than Clinique La Prairie or Lanserhof on the residential side because it is a different product.

For the reader who wants the comprehensive longevity workup — imaging plus deep bloodwork plus functional testing plus protocol design — YEARS at the outpatient end and Hirslanden at the hospital end will both run a sharper workup at the cost of a similar ticket once the Premium tier is factored in.

Note: not to be confused with AEON Clinic in Dubai, which is an unrelated regenerative-medicine practice with a substantially different business model.

An imaging-only product is structurally honest about what it does. Whether that is the product you want is the more important question.